leisure time -WSS

leisure time

author：focus 2025-10-01 22:16:40 - browse：68523

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How climate

hotspot

WSS

Xenotransplantation trials will require adjusting expectations, experts say

How climate

Beam Therapeutics to lay off 20% of its staff, re

CEOs share strategies for surviving biotech slump

Pharmacists can make shortage drugs, but at what cost?

Can medical device makers keep up in the race to treat obesity?

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

Researchers explore possible ties between long Covid, menopause

Alkermes shareholders re

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Anesthesiologist group: stop taking Ozempic before surgery

First Opinion Podcast: Long Covid needs a new approach

Trump demands the U.S. pay no more for drugs than other countries … again

Can medical device makers keep up in the race to treat obesity?

Tori Bowie and the unacceptable rates of Black maternal death

Studies point to risks of excluding people with obesity from drug trials

hotspot

Senate panel passes drug pricing bills, but drops one PBM reform

Reanimated hearts work just as well for transplants, study finds

How climate

First Opinion Podcast: Long Covid needs a new approach

Senate committee scrutinizes Medicare Advantage brokers

CEOs share strategies for surviving biotech slump

explore

hotspot

leisure time

leisure time